Last Price$60.00.0%
Market Cap$2,336.7M
N/A
Peers median - 14.7%
(824,137.5%)
Peers median - (0.9%)
1.4%
Peers median - 8.2%
(4,363.8%)
Peers median - (11.1%)
Competing with LBPH
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,336.7M | 5.9 | $11.2 81.3% overvalued | 1,170.8% | $8,000.0 | ($65.9M) | N/A | (824,137.5%) | 50.0% | (4,363.8%) | 1.4% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
Compare LBPH Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Longboard Pharmaceuticals, Inc.LBPH
256,495.0x
N/A
(4.8%)
N/A
Median Peer Set
4.0x
14.8%
(19.3%)
7.5%
Alnylam Pharmaceuticals, Inc.ALNY
13.0x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
BioNTech SEBNTX
2.0x
(77.4%)
(89.7%)
24.4%
Regeneron Pharmaceuticals, Inc.REGN
4.3x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
10.9x
11.7%
N/A
(4.9%)
Compare LBPH Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Longboard Pharmaceuticals, Inc. (LBPH) revenue growth compare to peers and the industry?
Longboard Pharmaceuticals, Inc. (LBPH) revenue growth is N/A, compared to the peers' median of 14.7%.
2. How does Longboard Pharmaceuticals, Inc. (LBPH) Free Cash Flow (FCF) margin compare to peers and the industry?
Longboard Pharmaceuticals, Inc. (LBPH) FCF margin is (824,137.5%), compared to the peers' median of (0.9%).
3. How does Longboard Pharmaceuticals, Inc. (LBPH) Total Debt to Equity ratio compare to peers and the industry?
Longboard Pharmaceuticals, Inc. (LBPH) Total Debt to Equity ratio is 1.4%, compared to the peers' median of 8.2%.
4. How does Longboard Pharmaceuticals, Inc. (LBPH) ROIC (Return on Invested Capital) compare to peers and the industry?
Longboard Pharmaceuticals, Inc. (LBPH) ROIC is (4,363.8%), compared to the peers' median of (11.1%).